Andrew McConaghie
Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
ASCO Data Show A Battle Ahead For Roche And Genmab’s Lymphoma Bispecifics
Roche looks set to gain first and second place in the race to bring CD3Xcd20s to market – but Genmab and AbbVie have a strong challenger.
CureVac Takes Another Shot At mRNA Vaccines, Expands Cancer Work
Its first COVID-19 vaccine failed last year, but fueled by payments from the EU, Germany and GSK, CureVac is trying again with two further versions of its mRNA platform.
Immunotherapy Biotech Genocea Closes Down As Sector Slump Deepens
The neoantigen immunotherapy company is a casualty of slow R&D progress and a squeeze on biotech finance – and more firms are in the firing line.
Vertex Spots Potential Bargain Of $60m Entry Into Complement Regulation
Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.
Zymeworks Rejects ‘Opportunistic’ Investor Takeover Bid
Activist investor All Blue wants to mount a takeover, but the biotech’s board is holding out for encouraging pipeline news to help fight off the bid.
Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck
Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.